Life Biosciences
Drug Developer
Recently, by Harvard biologistDavid SinclairCo-founded anti-aging biotechnology companyLife BiosciencesAnnouncement Completed8000Million USDDround of financing, for the clinical development and preclinical research advancement of its innovative anti-aging gene therapy.
This funding will primarily support the therapy for two vision loss conditions.1Clinical trials, which will also be used to explore the application of similar therapies in rejuvenation and repair of cells in other tissues and organs of the body.
This therapy is the world's first partial epigenetic reprogramming treatment to enter the clinical stage, with its core based on“Aging Results from the Loss of Epigenetic Information”The scientific hypothesis suggests that epigenetic codes can be rejuvenated by resetting three key proteins, rather than completely erasing them, theoretically avoiding the potential safety risks associated with full reprogramming.
This technology is based on Nobel Prize-level research in cell reprogramming and is also one of the core directions in the global field of cellular rejuvenation. It has previously attracted attention from tech investors such as Jeff Bezos and Sam Altman.
This Year1Month,Life BiosciencesApproved in the United StatesFDAApproval to launch the world's first clinical trial of partial epigenetic reprogramming gene therapy, becoming the leader in this field.
This clinical trial will target open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION) Two blinding diseases, aiming to repair damaged retinal ganglion cells and restore optic nerve function.
In the early stage of the trial, safety was the primary endpoint, while efficacy signals were also observed. The study规模较小，每个剂量组仅纳入3To6subjects, testing two dose levels, and multiple ocular indicators will be monitored. Chief Scientific Officer of the companySharon Rosenzweig-LipsonPointed out that the core objective of this study is to verify safety, and efficacy signals still need to await data results.
The therapy technology originates fromDavid SinclairLaboratory:2020In the year, the team confirmed in animal experiments that the removal of carcinogenic factorsc-MycLater, useOCT4、SOX2、KLF4Three Yamanaka factors can safely reset the epigenetic code and successfully reverse vision loss in a mouse model of glaucoma.Life BiosciencesAdoptAAV2Virus vector delivers three factor genes and is equipped with a molecular safety switch. Patients can activate or deactivate the therapy by taking oral medication. Animal experiments have verified that this system can be safely switched on and off multiple times within a year.
In addition to ophthalmic diseases, this round of financing will also support the preclinical exploration of the therapy in disease areas such as fatty liver. The company plans to disclose more research data on organs and diseases within the next one to two years.
As of now,Life BiosciencesThe cumulative financing amount is close to2.4Hundreds of millions of dollars, the new financing can support the company's operations until2027In the second half of the year, the information about the investors in this round of financing has not been disclosed yet.。
Source:endpoints news
